市場調查報告書
商品編碼
1383370
2030年數位糖尿病管理市場預測:按產品類型、最終用戶和地區分類的全球分析Digital Diabetes Management Market Forecasts to 2030 - Global Analysis By Product, Type, End User and By Geography |
根據 Stratistics MRC 的資料,2023年全球數位糖尿病管理市場規模將達到 189 億美元,預計到2030年將達到 521 億美元,預測期內年複合成長率為 15.6%。
糖尿病是一種影響體內血糖濃度的慢性疾病。此疾病主要是由於胰臟無法產生胰島素或穩定體內血糖濃度所引起的。糖尿病治療包括使用設備和應用來控制體內血糖值。使用這些小工具準確測量糖尿病不僅可以記錄和儲存資料,還有助於有效治療患者。
據世界衛生組織指出,2018年,糖尿病患者人數大幅增加,從1980年的1.08億增加到2014年的約4.22億。全球糖尿病盛行率已從 4.7%上升至 8.5%。2016年,約有160萬人死於糖尿病。
人工智慧(AI)是一個快速發展的領域,其在糖尿病診斷和治療中的配合措施徹底改變了治療這種長期疾病的方式。使用機器學習概念,開發了患有糖尿病和相關併發症可能性的預測模型。臨床決策支援對患者和醫療保健提供者都有好處,因為它使患者能夠控制糖尿病。這刺激市場擴張。
在許多地方,患者仍然更喜歡傳統的糖尿病管理方法。由於成本較低且缺乏對連網設備和應用程式的了解,許多患者避開數位平台,轉而選擇傳統的血糖監測。許多國家在糖尿病治療中缺乏智慧型手機、平板電腦和筆記型電腦的採用也阻礙了最尖端科技的普及。由於知識不足、缺乏合格人員和償付費用低,數位糖尿病照護變得越來越難以使用。
政府目的是提高糖尿病意識和方便用戶使用的胰島素管理設備介面的計劃推動了家庭護理環境中對數位糖尿病給藥設備的需求。由於消費者對科技先進產品的意識不斷增強,這些小工具在世界各地的使用越來越多。此外,糖尿病盛行率的顯著增加和政府宣傳宣傳活動也可能支持市場擴張。
與已開發國家相比,貧窮國家對技術先進的數位糖尿病管理平台的使用相對較少。這是由於基礎設施不足,國家電子醫療政策不明確,需要解決公眾對資料隱私和安全的擔憂,實現互通性的挑戰以及許多因素造成的,包括國內缺乏醫療資訊專業人員。國家和地區缺乏整合策略。這是阻礙市場拓展的因素。
數位糖尿病管理設備市場受到疫情的正面影響。當患有嚴重肺部感染疾病的患者被送往醫院時,控制血糖值變得極為重要。隨著藥物治療的給藥,患者的血糖值發生了顯著變化。此外,疾病管制與預防美國強調了被診斷患有糖尿病和 COVID-19 的患者面臨重症患者監護住院的高風險。因此,對管理糖尿病的設備的需求不斷增加。
由於與作為顯示設備的智慧型設備的兼容性等先進功能,連續血糖監測系統細分市場預計將在預測期內成為最大的細分市場。這是由於技術的持續進步,產品推出的增加,遠端監控技術與設備的整合以及社會意識的增強等因素。該技術的使用有助於即時監測患者的血糖值。還可以還可以全面了解每個人的血糖值。
預計醫院領域在預測期內的年複合成長率最高。醫院可以利用線上資源和行動應用程式為患者提供糖尿病資訊、自我管理工具和支援。使用這些技術,患者可以更佳了解自己的健康狀況、追蹤血糖值、管理藥物並接受醫療專業人員的指導。
由於先進技術的可用性以及許多數位血糖病患監測設備最近核准,預計北美將在預測期內保持最大的市場佔有率。有利的償付準則和政府支持將進一步促進產業擴張。此外,IT 公司和醫療保健提供者之間的合作也推動產業成長。
預計亞太地區在預測期內將維持最高的年複合成長率。該市場預計將因各種因素而發展,例如糖尿病患者數量的增加,醫療保健成本的上升以及該地區市場競爭數量的增加。對糖尿病和其他相關健康問題的健康意識不斷增強以及該地區可支配所得的增加預計將成為支持該區域市場擴張的額外因素。
According to Stratistics MRC, the Global Digital Diabetes Management Market is accounted for $18.9 billion in 2023 and is expected to reach $52.1 billion by 2030 growing at a CAGR of 15.6% during the forecast period. Diabetes is a chronic disease that affects the body's glucose levels. This illness is mostly brought on by the pancreas' failure to make insulin or to keep the body's glucose levels stable. Devices and applications are used in diabetes care to control blood glucose levels in the body. Using these gadgets to accurately measure diabetes aids in treating patients effectively as well as recording and retaining data.
According to WHO, in 2018, the number of people suffering with diabetes has significantly risen from 108 million in 1980 to approximately 422 million in 2014. The prevalence of diabetes across the glove has increased from 4.7% to 8.5%. In 2016, around 1.6 million deaths occurred due to diabetes.
Artificial intelligence (AI) is a fast developing field, and its applications in the diagnosis and treatment of diabetes have completely changed how we approach this long-term condition. Predictive models for the likelihood of acquiring diabetes and related complications have been developed using machine learning concepts. Clinical decision support is advantageous to both patients and healthcare providers since people are given more authority to control their diabetes on their own. This is fueling market expansion.
Patients still prefer the old-fashioned ways of managing their diabetes in many places. Many patients steer clear of digital platforms in favor of conventional blood glucose monitoring due to the cheap cost and lack of knowledge about connected devices and applications. The low uptake of smartphones, tablets, and laptops for diabetes treatment in various nations has also hampered the acceptability of cutting-edge technologies. Digital diabetes therapy has been made more difficult to use because to low knowledge, a shortage of qualified workers, and poor reimbursements.
Demand for digital diabetes management devices in homecare settings is being driven by government programs to increase diabetes awareness and user-friendly insulin delivery device interfaces. The increased use of these gadgets around the globe is due to rising consumer awareness of technologically advanced items. Additionally, a significant increase in the prevalence of diabetes and several government awareness campaigns might fuel market expansion.
Comparatively fewer technologically advanced digital diabetes management platforms are used in poorer nations than in industrialized ones. This is attributed to a number of factors, including insufficient infrastructure, hazy national e-health agendas, the need to allay public concerns about data privacy and security, challenges in achieving interoperability, a shortage of qualified health informatics professionals, and a lack of regional integration strategies. This is the element impeding market expansion.
The market for digital diabetes management devices was positively influenced by the epidemic. When patients with serious lung infections were brought to hospitals, controlling blood glucose levels became crucial. The patient's blood glucose levels significantly changed as a result of the disease-treating medications. Additionally, the Centers for Disease Control and Prevention underlined the elevated risk of admission to critical care that persons with diabetes and a COVID-19 diagnosis faced. Devices for managing diabetes become much more necessary as a result.
The continuous blood glucose monitoring system segment is expected to be the largest during the forecast period owing to its advanced features such as compatibility with smart devices that serve as display devices. This is attributed to the factors including on-going technical advancement, an increase in product introductions, more remote monitoring technology integration into devices, and expanding public awareness. The usage of this technology will make it easier to monitor a patient's blood glucose levels in real time. It also provides a complete picture of each person's blood glucose levels.
The hospitals segment is expected to have the highest CAGR during the forecast period. Hospitals can employ online resources or mobile applications that provide patients diabetes information, self-management tools, and support. With the use of these technologies, patients may have a better understanding of their health, track their blood sugar levels, manage their medication, and receive guidance from medical professionals.
North America is projected to hold the largest market share during the forecast period aided by the availability of advanced technologies and the recent approval of many digital blood glucose patient monitoring devices. Favorable reimbursement guidelines and governmental assistance further fuel industry expansion. Additionally, collaborations between IT firms and healthcare providers help the industry grow.
Asia Pacific is projected to hold the highest CAGR over the forecast period. This market is expected to develop as a result of a variety of factors, including an increase in the number of individuals with diabetes, growing healthcare costs, and an increase in the number of market competitors in the area. The expanding health awareness of diabetes and the other linked health issues, as well as the region's rising disposable income, are additional factors projected to support the expansion of this regional market.
Some of the key players in Digital Diabetes Management market include: Sanofi, Medtronic, Abbott Laboratories, Bayer AG, Insulet Corporation, Dexcom, Inc., F. Hoffmann-La Roche Ltd., Johnson and Johnson, B. Braun Melsungen AG, LifeScan, Inc., Terumo corporation., Ascensia Diabetes Care Holdings AG, Novo Nordisk A/S, AGaMatrix , Care Innovaions, LLC, Tandem Diabetes, DarioHealth Corporation and Decide Clinical Software GmbH.
In May 2023, Medtronic plc, a global leader in healthcare technology, announced definitive agreements for the acquisition of EOFlow Co. Ltd., manufacturer of wearable insulin patches to offer the benefits of automated insulin delivery and simplify diabetes treatment.
In April 2023, Glooko, Inc., a prominent software company, inked a Global partnership deal with Hedia, an insulin dosing algorithm company, to offer an interoperable solution that integrates remote patient monitoring, connected care, and digital therapeutic technologies to increase access to people with Type 1 and Type 2 diabetes in need of bolus insulin dosing advice.
In February 2023, Dexcom launched Dexcom G7 CGM device in the US and is planning to launch in Europe and Asia Pacific by first quarter of 2024.